Literature DB >> 17906592

Role of obesity on the risk for total hip or knee arthroplasty.

Robert Bourne1, Shaheena Mukhi, Naisu Zhu, Margaret Keresteci, Mihaela Marin.   

Abstract

We asked whether there was an association between obesity levels and subsequent THA or TKA using data from 54,406 THA and TKA patients entered into the Canadian Joint Replacement Registry. We compared these patients with a sample of the Canadian population using the Canadian Community Health Survey of 2006. We analyzed information from the Canadian Joint Replacement Registry to quantify the relative risk for THA or TKA in Canada for specific body mass index categories. In reference to the acceptable weight category of body mass index less than 25 kg/m2, the risk for TKA and THA was 3.20- and 1.92-fold higher, respectively, for overweight individuals (body mass index 25-29.9 kg/m2); 8.53- (TKA) and 3.42-fold (THA) higher for those in the obese Class I (body mass index 30-34.9 kg/m2) category; 18.73- (TKA) and 5.24-fold (THA) higher for those identified in obese Class II (body mass index 35-39.9 kg/m2); and 32.73- (TKA) and 8.56-fold (THA) higher for people in obese Class III group (body mass index > 40 kg/m2). Thus, our data support an association between obesity and subsequent THA and TKA.

Entities:  

Mesh:

Year:  2007        PMID: 17906592     DOI: 10.1097/BLO.0b013e3181576035

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  70 in total

1.  The relation between body mass index and waist-hip ratio in knee osteoarthritis.

Authors:  Rajiv Gandhi; Herman Dhotar; Dmitry Tsvetkov; Nizar N Mahomed
Journal:  Can J Surg       Date:  2010-06       Impact factor: 2.089

2.  Predictors of pain medication use for arthroplasty pain after revision total knee arthroplasty.

Authors:  Jasvinder A Singh; David G Lewallen
Journal:  Rheumatology (Oxford)       Date:  2014-01-22       Impact factor: 7.580

3.  The synovial fluid adiponectin-leptin ratio predicts pain with knee osteoarthritis.

Authors:  Rajiv Gandhi; Mark Takahashi; Holly Smith; Randy Rizek; Nizar N Mahomed
Journal:  Clin Rheumatol       Date:  2010-03-28       Impact factor: 2.980

4.  Hospital readmission rates following primary total hip arthroplasty: present and future in sight.

Authors:  José Lamo-Espinosa; Elena Pascual-Roquet Jalmar
Journal:  Ann Transl Med       Date:  2015-05

5.  Statistical Methods Dictate the Estimated Impact of Body Mass Index on Major and Minor Complications After Total Joint Arthroplasty.

Authors:  Mary J Kwasny; Adam I Edelstein; David W Manning
Journal:  Clin Orthop Relat Res       Date:  2018-12       Impact factor: 4.176

6.  Severe and morbid obesity (BMI ≥ 35 kg/m(2)) does not increase surgical time and length of hospital stay in total knee arthroplasty surgery.

Authors:  Luis M Lozano; Monserrat Tió; J Rios; Gerard Sanchez-Etayo; Dragos Popescu; Sergi Sastre; Misericordia Basora
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-04-26       Impact factor: 4.342

7.  Surgical Risks and Costs of Care are Greater in Patients Who Are Super Obese and Undergoing THA.

Authors:  Menachem M Meller; Nader Toossi; Mark H Gonzalez; Min-Sun Son; Edmund C Lau; Norman Johanson
Journal:  Clin Orthop Relat Res       Date:  2016-08-25       Impact factor: 4.176

8.  Morbid obesity may increase dislocation in total hip patients: a biomechanical analysis.

Authors:  Jacob M Elkins; Matej Daniel; Douglas R Pedersen; Bhupinder Singh; H John Yack; John J Callaghan; Thomas D Brown
Journal:  Clin Orthop Relat Res       Date:  2012-08-21       Impact factor: 4.176

9.  Predictors of pain and use of pain medications following primary Total Hip Arthroplasty (THA): 5,707 THAs at 2-years and 3,289 THAs at 5-years.

Authors:  Jasvinder A Singh; David Lewallen
Journal:  BMC Musculoskelet Disord       Date:  2010-05-13       Impact factor: 2.362

10.  The Canadian Joint Replacement Registry-what have we learned?

Authors:  Eric R Bohm; Michael J Dunbar; Robert Bourne
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.